Skip to content
flowss
Start freeChecking your session
Roadmap templates

Roadmap — Biotech R&D Pipeline by Asset and Phase

A five-year R&D portfolio roadmap for a fictional biotech with one lane per asset — an oral MASH candidate in Phase 2b, an antibody in Phase 1 and an oncology programme in IND-enabling studies — plus CMC and medical affairs: 13 items (2 done, 4 in progress, 6 planned, 1 at risk) and 6 milestones by half-year, status date 10 Feb 2027. All 14 dependencies finish before their dependents start, with each data readout gating the next phase, and the longest chain runs from the Phase 2b study through readout and the end-of-Phase 2 meeting to Phase 3. Illustrative roadmap.

RoadmapLife SciencesRoadmap syntax docs
Template previewRoadmap
Corvane Therapeutics — R&D pipeline roadmapCorvane Therapeutics — R&D pipeline roadmapThree clinical assets and the platform work behind them · each readout gates the next phaseDone 2In progress 4Planned 6At risk 16 milestones14 dependenciesStatus date 10 Feb 2027LANES · HALF-YEAR20262027202820292030H1H2H1H2H1H2H1H2H1H2MILESTONESToday · 10 Feb 2027CVN-101 · MASH, oral2 items · 2 milestonesCVN-204 · atopicdermatitis, antibody3 items · 1 milestoneCVN-310 · solidtumours, preclinical3 items · 1 milestone1 at riskCMC andmanufacturing3 itemsMedical affairs2 itemsPhase 2b dose-ranging, n = 240, 52 weeks · (H1 2026 .. H1 2027) · in progress · 80% · owner Clinical operationsPhase 2b topline readout · (2027-07-30) · milestone, plannedEnd-of-Phase 2 meeting · (2027-11-30) · milestone, plannedPhase 3 registrational programme · (H1 2028 .. H2 2030) · plannedPhase 1 SAD/MAD in healthy volunteers · (H2 2026 .. H1 2027) · in progress · 60%Phase 2a proof of concept, n = 120 · (H2 2027 .. H2 2028) · plannedProof-of-concept readout · (2029-03-29) · milestone, plannedPartnering process for Phase 3 · (2029-04 .. 2029-12) · plannedLead optimisation · (H1 2026) · doneIND-enabling GLP toxicology · (H2 2026 .. H1 2027) · at risk · owner NonclinicalIND submission · (2027-09-30) · milestone, plannedFirst-in-human dose escalation · (H1 2028 .. H2 2029) · plannedCommercial-scale API process for CVN-101 · (H2 2026 .. H2 2027) · in progress · 30%Process performance qualification · (H1 2028) · plannedGMP drug product for CVN-310 · (2027-01 .. 2027-08) · in progress · 10%MASH natural-history registry · (H1 2026 .. H2 2026) · doneHealth-economic model for MASH · (H1 2029 .. H2 2029) · plannedSeries C financing closed · (2026-03-20) · milestone, achievedPortfolio review with the board · (2027-12-10) · milestone, plannedPhase 2b dose-ranging, n = 240, 52 weeks · 80%Clinical operationsPhase 2b topline readoutEnd-of-Phase 2 meetingPhase 3 registrational programmePhase 1 SAD/MAD in healthy volunteers · 60%Phase 2a proof of concept, n = 120Proof-of-concept readoutPartnering process for Phase 3Lead optimisationIND-enabling GLP toxicologyNonclinicalIND submissionFirst-in-human dose escalationCommercial-scale API process for CVN-101 · 30%Process performancequalificationGMP drug product for CVN-310 · 10%MASH natural-history registryHealth-economic model for MASHSeries C financing closedPortfolio review with the boardCHECKS13 items in 5 lanes and 6 milestones: 2 done, 4 in progress, 6 planned, 1 at risk — every dependency finishes before its dependent starts.1 item at risk: “IND-enabling GLP toxicology”.Longest dependency chain: “Phase 2b dose-ranging, n = 240, 52 weeks” → “Phase 2b topline readout” → “End-of-Phase 2 meeting” → “Phase 3 registrational programme” (4 steps, ending 31 Dec 2030).All 14 dependencies finish before their dependents start.Nothing is past its date and unfinished as of 10 Feb 2027.Illustrative example: Corvane Therapeutics and its assets are fictional; trial sizes, durations and dates are invented and are not regulatory advice.

Make it your own.

title "Corvane Therapeutics — R&D pipeline roadmap"
subtitle "Three clinical assets and the platform work behind them · each readout gates the next phase"
note "Illustrative example: Corvane Therapeutics and its assets are fictional; trial sizes, durations and dates are invented and are not regulatory advice."
axis halves H1 2026 .. H2 2030
today 2027-02-10

milestone seriesc "Series C financing closed" 2026-03-20 done
milestone review "Portfolio review with the board" 2027-12-10 planned after readout

lane "CVN-101 · MASH, oral" color: emerald
  item p2b "Phase 2b dose-ranging, n = 240, 52 weeks" H1 2026 .. H1 2027 in progress 80% owner: "Clinical operations"
  milestone readout "Phase 2b topline readout" 2027-07-30 planned after p2b
  milestone eop2 "End-of-Phase 2 meeting" 2027-11-30 planned after readout
  item p3 "Phase 3 registrational programme" H1 2028 .. H2 2030 planned after eop2

lane "CVN-204 · atopic dermatitis, antibody" color: violet
  item sad "Phase 1 SAD/MAD in healthy volunteers" H2 2026 .. H1 2027 in progress 60%
  item p2a "Phase 2a proof of concept, n = 120" H2 2027 .. H2 2028 planned after sad
  milestone poc "Proof-of-concept readout" 2029-03-29 planned after p2a
  item partner "Partnering process for Phase 3" 2029-04 .. 2029-12 planned after poc

lane "CVN-310 · solid tumours, preclinical" color: rose
  item lead "Lead optimisation" H1 2026 done
  item tox "IND-enabling GLP toxicology" H2 2026 .. H1 2027 at risk after lead owner: "Nonclinical"
  milestone ind "IND submission" 2027-09-30 planned after tox, cmc310
  item fih "First-in-human dose escalation" H1 2028 .. H2 2029 planned after ind

lane "CMC and manufacturing" color: amber
  item api "Commercial-scale API process for CVN-101" H2 2026 .. H2 2027 in progress 30%
  item ppq "Process performance qualification" H1 2028 planned after api
  item cmc310 "GMP drug product for CVN-310" 2027-01 .. 2027-08 in progress 10%

lane "Medical affairs" color: sky
  item registry "MASH natural-history registry" H1 2026 .. H2 2026 done
  item heor "Health-economic model for MASH" H1 2029 .. H2 2029 planned after registry, eop2